Skip to main content
. Author manuscript; available in PMC: 2016 Aug 29.
Published in final edited form as: Leukemia. 2016 Feb 29;30(7):1456–1464. doi: 10.1038/leu.2016.46

Figure 1. Association between pre-transplant disease status and outcome for 279 AML patients undergoing myeloablative HCT while in morphologic remission.

Figure 1

Estimates of (A) overall survival, (B) relapse-free survival, (C) cumulative risk of relapse, and (D) cumulative risk of non-relapse mortality following myeloablative allogeneic HCT for adults with AML who underwent bone marrow assessments with MFC before as well as on day +28 (± 7 days) after transplantation. Outcome estimates are shown individually for patients in MRDneg remission 1 (n=167), MRDneg remission 2 (n=49), MRDpos remission 1 (n=43), and MRDpos remission 2 (n=20) at the time of transplantation, respectively.